{'fraction_non_alphanumeric': 0.03418803418803419, 'fraction_numerical': 0.017094017094017096, 'mean_word_length': 4.579365079365079, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Pharmacokinetics of 2-pivaloylindan-1,3-dione in dogs.

The pharmacokinetics of 2-pivaloylindan-1,3-dione (Pival) after administration of a single dose was investigated in dogs. The plasma concentration graph can be described by a one compartment open model. The drug is fairly well adsorbed (67%) and the excretion is extremely slow with a half-life of nearly five days. These kinetics can be explained by the physiochemical properties of the drug, such as strong binding to canine plasma protein, high lipophility and the lack of transformation to polar metabolites. A single oral dose of 5 mg/kg must be regarded as lethal to dogs and the LD50 is assumed to be approximately 4 mg/kg in this species.